Searched for
CRDMO
Sai Life Sciences shares rally 9% after Q2 results; net profit rises 17%, revenue up 23%Sai Life Sciences shares jumped nearly 9% to a fresh 52-week high after strong second-quarter results. Revenue rose 23%, while net profit i...- Jefferies lists 6 factors that will shape CRDMO winners; Divi’s Labs, Sai Life, Laurus, Anthem among stocks to watchIndia's CRDMO sector is on the brink of expansion, backed by solid partnerships with major pharmaceutical players and comprehensive capabil...
- MF Tracker: HDFC Pharma & Healthcare Fund tops equity MFs at 25% in 1 year. Should investors chase the rally?HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time fra...
- Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacityAragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-mol...
- How PGIM India's Rs 112 crore Healthcare Fund picks CDMO stocks to generate alphaPGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...
- Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka BioCohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thir...
- Aragen Life Sciences files draft papers with Sebi to raise funds through IPOAragen Life Sciences has filed its DRHP with Sebi for an IPO comprising a Rs 800 crore fresh issue and an OFS. Proceeds will fund debt repa...
- Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 targetJefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is ...
- Nomura initiates coverage on this recently-listed CRDMO stock, sees 18% upside despite 22% correctionNomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positio...
- Biocon shares in focus as company swings to Rs 84 crore profit in Q2Biocon reported a strong turnaround in Q2FY26 with a net profit of Rs 84.5 crore against a loss of Rs 16 crore last year, driven by 21% YoY...
- Jefferies' pharma bets are Divi's Laboratories and 3 smallcaps, with up to 30% upside. Here's whyJefferies expects India’s CRDMO sector to see strong growth over 3–5 years, recommending Divi’s Labs, Cohance Lifesciences, Sai Life Scienc...
- Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendationCohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...
- Avendus Fund, SBI Life lead funding in AragenAvendus Future Leaders Fund and SBI Life Insurance have collectively invested ₹300 crore in Aragen Life Sciences, acquiring a 2.5% stake in...
- Anthem Biosciences' Rs 3,395 crore IPO opens for subscription. Should you bid?Anthem Biosciences launched its IPO on July 14, featuring an offer for sale of Rs 3,395 crore. The Bengaluru-based CRDMO, with a price band...
- Is Anthem Biosciences IPO a risky bet for investors?Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit h...
- Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CR...
- India's CRDMO sector can touch USD 25 bn in size by 2035: ReportIndia's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing pressures, and demand...
- India becoming an attractive option for global pharmaceutical supply chain: Macquarie ReportIndia's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...
- Anthem Biosciences files DRHP for Rs 3,395 crore IPOAnthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors....
- Sai Life Science grew fast, but pricing looks expensiveThe issue gives a partial exit to private equity investors TPG Asia and HBM. The promoter share will be diluted from 41.8% to 35.2%. The is...
Load More
